Inovio Wins Deloitte’s “Fast 500” Growth Award
November 16 2016 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced it
ranked No. 107 on Deloitte’s Technology Fast 500™, a ranking of the
500 fastest growing technology, media, telecommunications, life
sciences and energy tech companies in North America. Technology
Fast 500 award winners are selected based on percentage fiscal year
revenue growth from 2012 to 2015. During this period Inovio’s
revenue growth reached 885.1%, based on revenue received from
grants, partnerships and licensing deals.
Dr. J. Joseph Kim, Inovio's President and CEO,
said, “We appreciate Deloitte’s recognition of Inovio’s growth
based on our advancement of DNA immunotherapies and vaccines for
cancers and infectious diseases. Our growth is fueled by the
innovative spirit of our scientists, engineers and business
people. At our company’s core; however, the Inovio team is
motivated by our most important value: ‘Patients are waiting.’”
“This year’s Fast 500 winners showcase that when
organizations are open to diverse perspectives and insights, they
are able to create an environment for their employees and investors
to see the possibilities and ingenious solutions that might lie
ahead,” added Jim Atwell, Deloitte’s national managing partner of
the emerging growth practice. “Entrepreneurial environments foster
change and innovation within businesses, and we look forward to
watching these companies continue to drive change across all
sectors.”
About Deloitte’s 2016 Technology Fast 500™
Deloitte’s Technology Fast 500 provides a
ranking of the fastest growing technology, media,
telecommunications, life sciences and energy tech companies – both
public and private – in North America. Technology Fast 500 award
winners are selected based on percentage fiscal year revenue growth
from 2012 to 2015. Overall, 2016 Technology Fast 500™ companies
achieved revenue growth ranging from 121 percent to 66,661 percent
from 2012 to 2015, with median growth of 290 percent.
In order to be eligible for Technology Fast 500
recognition, companies must own proprietary intellectual property
or technology that is sold to customers in products that contribute
to a majority of the company's operating revenues. Companies must
have base-year operating revenues of at least $50,000 USD, and
current-year operating revenues of at least $5 million USD.
Additionally, companies must be in business for a minimum of four
years and be headquartered within North America.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, The Wistar Institute, University of Pennsylvania, DARPA,
GeneOne Life Science, Plumbline Life Sciences, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and Laval University. For more
information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs and our capital resources. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials and product
development programs, including the Zika vaccine GLS-5700, the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active
immunotherapy and vaccine products, the ability of our
collaborators to attain development and commercial milestones for
products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital
resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost effective than any therapy or treatment
that the company and its collaborators hope to develop, issues
involving product liability, issues involving patents and whether
they or licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2015,
our Form 10-Q for the quarter ended September 30,
2016, and other regulatory filings from time to time. There
can be no assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024